New cocktail aims to shrink rectal tumors before surgery
NCT ID NCT07150949
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tests whether adding an immunotherapy drug (serplulimab) and a COX-2 inhibitor (celecoxib) to standard chemoradiotherapy can improve outcomes for people with locally advanced rectal cancer. 138 participants will receive either long-course or short-course radiation plus chemotherapy, with the new drugs added. The main goal is to see how many patients have a complete response, meaning no cancer remains after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Oxaliplatin, capecitabine, serplulimab (PD-1 antibody), and celecoxib (COX-2 inhibitor)
What this could lead to
If successful, this combination could increase the chance of eliminating the tumor before surgery, potentially allowing some patients to avoid surgery altogether.
What could go wrong
This is an early phase II trial with only 138 participants, so results may not apply to everyone. Adding immunotherapy and a COX-2 inhibitor may increase side effects like immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••